Treatment and survival for women with fallopian tube carcinoma: A population-based study

Carol Kosary, Edward Trimble

Research output: Contribution to journalArticle

Abstract

Objective. The objective of this study was to evaluate treatment and survival for women with fallopian tube carcinoma in a population-based data set. Methods. Using the National Cancer Institute's Surveillance, Epidemiology, and End Results program, we identified 416 women with fallopian tube carcinoma diagnosed between 1990 and 1997. We analyzed treatment and 5-year relative survival. We also compared survival to that of 9032 women with epithelial ovarian cancer diagnosed between 1991 and 1997. Results. Almost half of those diagnosed with stage I/II disease did not undergo surgical evaluation of lymph nodes. Most women with stage I/II disease were treated with surgery alone, while most women with stage III/IV disease were treated with surgery and chemotherapy. Five-year relative survival by FIGO stage was as follows: stage I (N = 102), 95%; stage II (N = 29), 75%; stage III (N = 52), 69%; stage IV (N = 151), 45%. Conclusions. We observed better survival, stage by stage, for women with fallopian tube carcinoma than for women with epithelial ovarian cancer in this population-based data set. It is possible that some patients with advanced, bulky carcinoma arising in the fallopian tube may have been classified as having ovarian or primary peritoneal cancer. Women with fallopian tube cancer should be treated in accordance with the same guidelines for surgical staging, debulking, and adjuvant chemotherapy as for women with epithelial ovarian cancer. Further studies, both laboratory and clinical, are needed to delineate the differences between fallopian and ovarian cancers.

Original languageEnglish (US)
Pages (from-to)190-191
Number of pages2
JournalGynecologic Oncology
Volume86
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Fallopian Tubes
Carcinoma
Survival
Population
Therapeutics
Fallopian Tube Neoplasms
SEER Program
National Cancer Institute (U.S.)
Adjuvant Chemotherapy
Ovarian Neoplasms
Lymph Nodes
Guidelines
Drug Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Treatment and survival for women with fallopian tube carcinoma : A population-based study. / Kosary, Carol; Trimble, Edward.

In: Gynecologic Oncology, Vol. 86, No. 2, 2002, p. 190-191.

Research output: Contribution to journalArticle

@article{e908e2f796094b4b99a7564758a0318a,
title = "Treatment and survival for women with fallopian tube carcinoma: A population-based study",
abstract = "Objective. The objective of this study was to evaluate treatment and survival for women with fallopian tube carcinoma in a population-based data set. Methods. Using the National Cancer Institute's Surveillance, Epidemiology, and End Results program, we identified 416 women with fallopian tube carcinoma diagnosed between 1990 and 1997. We analyzed treatment and 5-year relative survival. We also compared survival to that of 9032 women with epithelial ovarian cancer diagnosed between 1991 and 1997. Results. Almost half of those diagnosed with stage I/II disease did not undergo surgical evaluation of lymph nodes. Most women with stage I/II disease were treated with surgery alone, while most women with stage III/IV disease were treated with surgery and chemotherapy. Five-year relative survival by FIGO stage was as follows: stage I (N = 102), 95{\%}; stage II (N = 29), 75{\%}; stage III (N = 52), 69{\%}; stage IV (N = 151), 45{\%}. Conclusions. We observed better survival, stage by stage, for women with fallopian tube carcinoma than for women with epithelial ovarian cancer in this population-based data set. It is possible that some patients with advanced, bulky carcinoma arising in the fallopian tube may have been classified as having ovarian or primary peritoneal cancer. Women with fallopian tube cancer should be treated in accordance with the same guidelines for surgical staging, debulking, and adjuvant chemotherapy as for women with epithelial ovarian cancer. Further studies, both laboratory and clinical, are needed to delineate the differences between fallopian and ovarian cancers.",
author = "Carol Kosary and Edward Trimble",
year = "2002",
doi = "10.1006/gyno.2002.6743",
language = "English (US)",
volume = "86",
pages = "190--191",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment and survival for women with fallopian tube carcinoma

T2 - A population-based study

AU - Kosary, Carol

AU - Trimble, Edward

PY - 2002

Y1 - 2002

N2 - Objective. The objective of this study was to evaluate treatment and survival for women with fallopian tube carcinoma in a population-based data set. Methods. Using the National Cancer Institute's Surveillance, Epidemiology, and End Results program, we identified 416 women with fallopian tube carcinoma diagnosed between 1990 and 1997. We analyzed treatment and 5-year relative survival. We also compared survival to that of 9032 women with epithelial ovarian cancer diagnosed between 1991 and 1997. Results. Almost half of those diagnosed with stage I/II disease did not undergo surgical evaluation of lymph nodes. Most women with stage I/II disease were treated with surgery alone, while most women with stage III/IV disease were treated with surgery and chemotherapy. Five-year relative survival by FIGO stage was as follows: stage I (N = 102), 95%; stage II (N = 29), 75%; stage III (N = 52), 69%; stage IV (N = 151), 45%. Conclusions. We observed better survival, stage by stage, for women with fallopian tube carcinoma than for women with epithelial ovarian cancer in this population-based data set. It is possible that some patients with advanced, bulky carcinoma arising in the fallopian tube may have been classified as having ovarian or primary peritoneal cancer. Women with fallopian tube cancer should be treated in accordance with the same guidelines for surgical staging, debulking, and adjuvant chemotherapy as for women with epithelial ovarian cancer. Further studies, both laboratory and clinical, are needed to delineate the differences between fallopian and ovarian cancers.

AB - Objective. The objective of this study was to evaluate treatment and survival for women with fallopian tube carcinoma in a population-based data set. Methods. Using the National Cancer Institute's Surveillance, Epidemiology, and End Results program, we identified 416 women with fallopian tube carcinoma diagnosed between 1990 and 1997. We analyzed treatment and 5-year relative survival. We also compared survival to that of 9032 women with epithelial ovarian cancer diagnosed between 1991 and 1997. Results. Almost half of those diagnosed with stage I/II disease did not undergo surgical evaluation of lymph nodes. Most women with stage I/II disease were treated with surgery alone, while most women with stage III/IV disease were treated with surgery and chemotherapy. Five-year relative survival by FIGO stage was as follows: stage I (N = 102), 95%; stage II (N = 29), 75%; stage III (N = 52), 69%; stage IV (N = 151), 45%. Conclusions. We observed better survival, stage by stage, for women with fallopian tube carcinoma than for women with epithelial ovarian cancer in this population-based data set. It is possible that some patients with advanced, bulky carcinoma arising in the fallopian tube may have been classified as having ovarian or primary peritoneal cancer. Women with fallopian tube cancer should be treated in accordance with the same guidelines for surgical staging, debulking, and adjuvant chemotherapy as for women with epithelial ovarian cancer. Further studies, both laboratory and clinical, are needed to delineate the differences between fallopian and ovarian cancers.

UR - http://www.scopus.com/inward/record.url?scp=0036351515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036351515&partnerID=8YFLogxK

U2 - 10.1006/gyno.2002.6743

DO - 10.1006/gyno.2002.6743

M3 - Article

C2 - 12144827

AN - SCOPUS:0036351515

VL - 86

SP - 190

EP - 191

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -